Vertex Pharmaceuticals (VRTX) Shares Outstanding (Weighted Average) (2009 - 2026)

Vertex Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 18 years, with the latest figure at $254.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 1.09% year-over-year to $254.1 million; the trailing twelve-month figure through Mar 2026 stood at $254.1 million (down 1.09% YoY), and the FY2025 full-year result was $255.7 million, down 0.85% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $254.1 million, down from $255.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $258.2 million in Q1 2024, with the low at $254.1 million in Q1 2026.
• Average Shares Outstanding (Weighted Average) over 5 years is $256.7 million, with a median of $256.9 million recorded in 2025.
• Year-over-year, Shares Outstanding (Weighted Average) decreased 1.66% in 2022 and increased 0.9% in 2023.
• Tracing VRTX's Shares Outstanding (Weighted Average) over 5 years: stood at $256.1 million in 2022, then grew by 0.62% to $257.7 million in 2023, then advanced by 0.08% to $257.9 million in 2024, then fell by 0.85% to $255.7 million in 2025, then dropped by 0.63% to $254.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $254.1 million (Q1 2026), $255.7 million (Q4 2025), and $255.6 million (Q3 2025), per Business Quant data.

Peer Comparison